查看文章

Chronic migraine is an extremely common disorder that greatly impacts the quality of life of the sufferer. Chronic migraine affects up to 2% of the general population and within the United States alone accounts for almost 3 millions Americans. Despite the high prevalence for this disorder and the recent breakthroughs that have been achieved, therapeutic strategies for the treatment of migraine are still limited. With the recent addition of the calcitonin gene related peptide (CGRP) antibodies some patients with chronic migraine who previously had poor response to available migraine pharmaceutics finally experienced a reduction in headache days per month. While these advancements are great and show the therapeutic potential that can be gained from exploring migraine pathophysiology there is still not a migraine therapeutic that is effective in all people nor is there a cure to migraine. Gaining a better …